New therapeutic agents for metastatic colorectal cancer: literature review
https://doi.org/10.17650/2220-3478-2018-8-4-34-46
Abstract
This article provides an overview of drugs for metastatic colorectal cancer that are currently being evaluated in clinical trials. We discuss possible drug combinations and outlooks of their use in different lines of therapy. In addition to VEGF and EGFR inhibitors, we describe the molecules with fundamentally new mechanisms of action that can significantly expand the list of anticancer agents and increase the number of possible lines of therapy.
About the Authors
M. V. Zabelin
National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2ndBotkinskiy Proezd, Moscow 125284.
Russian Federation
3 2ndBotkinskiy Proezd, Moscow 125284.
S. S. Gordeev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
S. O. Kochkina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
A. A. Kostin
National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
3 2ndBotkinskiy Proezd, Moscow 125284.
Russian Federation
3 2ndBotkinskiy Proezd, Moscow 125284.
A. A. Fedenko
P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
3 2nd Botkinsky Proezd, Moscow 125284.
Russian Federation
3 2nd Botkinsky Proezd, Moscow 125284.
L. O. Petrov
A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Russian Federation
4Koroleva St., Obninsk 249036.
Russian Federation
4Koroleva St., Obninsk 249036.
E. V. Gameeva
P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Radiology Research Center, Ministry of Health of Russia
Russian Federation
3 2nd Botkinsky Proezd, Moscow 125284.
Russian Federation
3 2nd Botkinsky Proezd, Moscow 125284.
References
1. Lukashina M.I., Smirnova A.V., Aliev V.A. et al. Dendritic cell vaccines for colorectal cancer therapy. Vestnik RONC im. N.N. Blokhina RAMN = Journal of N.N. Blokhin Russian Cancer Research Center 2008;19(3):35–42. (In Russ.).
2. Akylbekova G.A., Abdylaev G.A. Current possibilities of chemotherapy for colorectal cancer (literature review). Izvestiya vuzov = Proceedings of Universities 2013;5:53–7. (In Russ.).
3. Smagulova K. Assessing quality of life in patients treated for metastatic colon and rectal cancer. Uspekhi sovremennoy nauki = Advances of Modern Science 2017;1(6):81–3. (In Russ.).
4. Fedyanin M.Yu., Tryakin A.A., Tjulandin S.A. Targeted drugs in the treatment of colon cancer. Onkologiya, gematologiya i radiologiya = Oncology, Hematology, and Radiology 2012;3:30–6. (In Russ.).
5. Hoff P.M., Ansari R., Batist G. et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282–92. PMID: 11304782. DOI: 10.1200/JCO.2001.19.8.2282.
6. Colucci G., Gebbia V., Paoletti G. et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866–75. PMID: 15939922. DOI: 10.1200/JCO.2005.07.113.
7. Díaz-Rubio E., Tabernero J., Gómez-España A. et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25(27):4224–30. PMID: 17548839. DOI: 10.1200/JCO.2006.09.8467.
8. Kuipers E.J., Grady W.M., Lieberman D. et al. Colorectal cancer. Nat Rev Dis Primers 2015;1:15065.
9. Tryakin A.A. Targeted therapy for colorectal, gastric, and pancreatic cancer. Prakticheskayaonkologiya = Practical Oncology 2010;11(3):143—50. (In Russ.).
10. Amado R.G., Wolf M., Peeters M. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(10):1626—34. PMID: 18316791. DOI: 10.1200/JCO.2007.14.7116.
11. Douillard J.Y., Oliner K.S., Siena S. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023—34. PMID: 24024839. DOI: 10.1056/NEJ-Moa1305275.
12. Bokemeyer C., Bondarenko I., Makhson A. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71. PMID: 19114683. DOI: 10.1200/JCO.2008.20.8397.
13. Susman E. Rash correlates with tumour response after cetuximab. Lancet Oncol 2004;5(11):647. PMID: 15536688.
14. Van Cutsem E., Kohne C.H., Hitre E. et al. Cetuximab and chemotherapy as ini¬tial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14): 1408-17. PMID: 19339720. DOI: 10.1056/NEJMoa0805019.
15. Vladimirova L.Yu., Abramova N.A., Storozhakova A.E. Targeted therapy with anti-EGFR-monoclonal antibodies for colorectal cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;4( special issue 1):87—91. (In Russ.).
16. Gorchakov S.V., Pravosudov I.V., Vasilyev S.V. et al. Multidisciplinary approach to the treatment of colorectal cancer with liver metastases: oncologist's view. Povolzhskiy onkologicheskiy vestnik = Oncology Bulletin of the Volga Region 2015;4;70—8. (In Russ.).
17. Gorchakov S.V., Pravosudov I.V., Vasilyev S.V. et al. Current approaches to the treatment of colorectal cancer with liver metastases: literature review. Vestnik SPbGU = Bulletin of Saint Petersburg University 2015;11(3):55—68. (In Russ.).
18. Burqdorf S.K. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull 2010;57(9):B4171. PMID: 20816019.
19. Burris H.A., Infante J.R., Ansell S.M. et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol 2017;35(18):2028—36. PMID: 28463630. DOI: 10.1200/JCO.2016.70.1508.
20. Elez E., Hendlisz A., Delaunoit T. et al. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or meta¬static colorectal cancer. Br J Cancer 2016;114:372—80. PMID: 26766738. DOI: 10.1038/bjc.2015.480.
21. Artamonova E.V. Cetuximab in the treatment of metastatic colorectal cancer: skin toxicity and methods to address it. Onkologicheskaya koloproktologiya = Colorectal Oncology 2011;3:21—7. (In Russ.).
22. Dobrova N.V. Cetuximab in the treatment of metastatic colorectal cancer. Onkologiya, gematologiya i radiologiya = Oncology, Hematology, and Radiology 2012;2:24—9. (In Russ.).
23. Perevodchikova N. Targeted drugs and their role in cancer treatment. Klinicheskaya onkogematologiya = Clinical Oncohematology 2009;2(4):367—73. (In Russ.).
24. Sobrero A.F., Maurel J., Fehrenbacher L. et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with meta¬static colorectal cancer. J Clin Oncol 2008;26(14):2311—9. PMID: 18390971. DOI: 10.1200/JCO.2007.13.1193.
25. Karapetis C.S., Khambata-Ford S., Jonker D.J. et al. KRAS mutations and be-nefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757—65. PMID: 18946061. DOI: 10.1056/NEJMoa0804385.
26. Vorontsova K.A., Dobrova N.V., Vyshinskaya G.V. Second-line anticancer therapy for metastatic colorectal cancer: treatment strategy. Meditsinskiy sovet = Medical Council 2015;8:55—9. (In Russ.).
27. Vorontsova K.A., Chernoglazova E.V., Vyshinskaya G.V. Targeted drugs in second-line therapy for disseminated colorectal cancer. Meditsinskiy sovet = Medical Council 2015;8:91—6. (In Russ.).
28. Kuznetsova O.M., Khadasheva Z.S., Smirnova I.P. Vascular endothelial growth factor inhibitors and tyrosine kinase receptor inhibitors as new antiangiogenic agents for anticancer therapy. Vestnik Chechenskogo gosudarstvennogo universiteta = Bulletin of the Chechen State University 2007;4(24):60—6. (In Russ.).
29. Feoktistova P.S., Zaginayko A.V., Karaseva V.V., Khaylenko V.A. Targeted therapy for metastatic colorectal cancer. Zdravookhranenie Yugry: opyt i innovatsii = Health Care in Ugra: Experience and Innovations 2016;C:76—84. (In Russ.).
30. Price T.J., Peeters M., Kim T.W. et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15(6):569—79. PMID: 24739896. DOI: 10.1016/S1470-2045(14)70118-4.
31. Douillard J.Y., Siena S., Cassidy J. et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25(7):1346—55. PMID: 24718886. DOI: 10.1093/annonc/mdu141.
32. Safety study of GC1118 (Recombinant Human Anti-EGFR Antibody) in patients with advanced solid cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02352571?cond=GC1118&rank=1.
33. Gan H.K., Seruga B., Knox J.J. Sunitinib in solid tumors. Expert Opin Investig Drugs 2009;18(6):821—34. DOI: 10.1517/13543780902980171.
34. Zhou J., Lin Sh., Jing G. A dose escala-tion study of nimotuzumab plus irinotecan as second-line treatment in metastatic colorectal cancer with wild-type KRAS. J Clin Oncol 2012:30(15 suppl):e14122. DOI: 10.1200/jco.2012.30.15_suppl.e14122.
35. Zhou Y., Shen L., Zheng J. P50 dose-es-calation study of nimotuzumab plus irinotecan as second-line treatment in meta static colorectal cancer with wild-type KRAS. EJC Supplements 2011;9:20.
36. Dienstmann R., Patnaik A., Garcia-Carbonero R. et al. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refrac-tory colorectal cancer. Cancer Discov 2015;5(6):598—609. DOI: 10.1158/2159-8290.CD-14-1432.
37. Lynch D., Murphy A. The emerging role of immunotherapy in colorectal cancer. Ann Transl Med 2016;4(16):305. DOI: 10.21037/atm.2016.08.29.
38. Stanculeanu D.L., Daniela Z., Lazescu A. et al. Development of new immunotherapy treatments in different cancer types. J Med Life 2016;9(3):240-8. PMID: 27974927.
39. Becerra A.Z., Probst P., Tejani M.A. et al. Evaluating the prognostic role of elevated preoperative carcinoembryonic antigen levels in colon cancer patients: results from the national cancer database. Ann Surg Oncol 2016;23(5):1554—61. PMID: 26759308. DOI: 10.1245/s10434-015-5014-1.
40. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. PMID: 15175435. DOI: 10.1056/NEJMoa032691.
41. Liu K.-J., Chao T.-Y., Chang J.-Y. et al. A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment. J Biomed Sci 2016;23(1):1—11. PMID: 27558635. DOI: 10.1186/s12929-016-0279-7.
42. Cremolini C., Loupakis F., Antoniotti C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16(13):1306-15. PMID: 26338525. DOI: 10.1016/S1470-2045(15)00122-9.
43. Oki E., Kato T., Bando H. et al. A multi-center clinical phase II study of FOLFOX-IRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. Clin Colorectal Cancer 2018;17(2):147-55. PMID: 29530335. DOI: 10.1016/j.clcc.2018.01.011.
44. Giantonio B.J., Catalano P.J., Meropol N.J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539—44. PMID: 17442997. DOI: 10.1200/JCO.2006.09.6305.
45. Yamaguchi K., Taniguchi H., Komori A. et al. A single-arm phase II trial of com-bined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pretreated patients with metastatic colorectal cancer. BMC Cancer 2015;15:601. PMID: 26311588. DOI: 10.1186/s12885-015-1606-1.
46. Yakusheva T.A., Kogoniya L.M., Fedotov A.Yu. et al. Avastin in the treatment of metastatic colorectal cancer. Rossiyskiy bioterapevtycheskiy zhurnal = Russian Biotherapeutic Journal 2010;4(9):35—8. (In Russ.).
47. Mikhaylova N.V., Fayrushina A.N. Current approach to colorectal cancer therapy. Targeted therapy for metastatic colorectal cancer. Povolzhskiy onkologicheskiy vestnik = Oncology Bulletin of the Volga Region 2016;3(25):80—4. (In Russ.).
48. Ciprotti M., Tebbutt N.C., Lee F.T. et al. Phase I imaging and pharmacodynamic trial of CS-1008 in patients with metastat¬ic colorectal cancer. J Clin Oncol 2015;33(24):2609—616. PMID: 26124477. DOI: 10.1200/JCO.2014.60.4256.
49. Amin M. The potential role of immuno-therapy to treat colorectal cancer. Exp Opin Investig Drugs 2015;(3):329—44. PMID: 25519074. DOI: 10.1517/13543784.2015.985376.
50. Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499—506. PMID: 22949147. DOI: 10.1200/JCO.2012.42.8201.
51. Ruff P., van Cutsem E., Lakomy R. et al. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. J Geriatr Oncol 2018;9(1):32—9. PMID: 28807738. DOI: 10.1016/j.jgo.2017.07.010.
52. Pastorino A., Di Bartolomeo M., Maiello E. et al. Aflibercept plus FOLFIRI in the real-life setting: safety and quality of life data from the italian patient cohort of the aflibercept safety and quality-of-life program study. Clin Colorectal Cancer 2018. PII: S1533-0028(18)30050-1.
53. Bordonaro R., Sobrero A.F., Frassineti L. et al. Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients >65. J Clin Oncol 2014;1:545.
54. Likhova E.A., Yukalchuk D.Yu., Ponomarenko D.M., Shevchuk A.V. Aflibercept in second-line therapy for metastatic colorectal cancer: clinical experience. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2017;20:38-40. (In Russ.).
55. Segelov E., Chan D., Shapiro J. et al. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomized trials. Br J Cancer 2014;111(6):1122-31. PMID: 25072258.
56. Francoso A., Simioni P.U. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther 2017;11:177-84. PMID: 28138221. DOI: 10.2147/DDDT.S119036.
57. Lin E.H. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal anti-body robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med 2014;3(4):988—97. PMID: 24905030. DOI: 10.1002/cam4.263.
58. Patnaik A., LoRusso P.M., Messersmith WA. et al. Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chenother Pharmacol 2014;73(5):951—60. PMID: 24633809. DOI: 10.1007/s00280-014-2426-8.
59. Weekes C.D. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs 2014;32(4):653—60. PMID: 24604265.
60. Fedyanin M.Yr., Tryakin AA, Tjulandin S.Yu. Potential predictors of the efficacy of anti-EGFR therapy in metastatic colon cancer. Onkologicheskaya proktologiya = Proctologic Oncology 2013;2:21-30. (In Russ.).
61. Sekacheva M.I. Regorafenib: new drug for metastatic colorectal cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;2(18):69—76. (In Russ.).
62. Ohhara Y., Fukuda N., Takeuchi S. et al. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016;8(9):642-55.
63. Yoshino T., Komatsu Y., Yamada Y. et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and nonJapanese subpopulations. Invest New Drugs 2015;33(3):740—50. PMID: 25213161. DOI: 10.1007/s10637-014-0154-x.
64. Goel G. Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug? Cancer Manag Res 2018;10:425-37. PMID: 29563833. DOI: 10.2147/CMAR.S88825.
65. Korytova L.I., Tarazov P.G., Gopta E.V., Polikarpov A.A. Radiotherapy in the combination treatment of colorectal cancer with liver metastases. Palliativnaya meditsina i reabilitatsiya = Palliative Care and Rehabilitation 2009;3:27-30. (In Russ.).
66. Lassen U.N., Meulendijks D., Siu L.L. et al. A phase I monotherapy study of RG7112, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. Clin Cancer Res 2015;21(2):258-66.
67. Clinical Study Report CS1008-A-E203. Version 1.0, 2012. 7 p.
68. Rocha Lima C.M., Bayraktar S., Flores A.M. et al. Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with meta-static colorectal cancer. Cancer Invest 2012;30(10):727—31. PMID: 23061802. DOI: 10.3109/07357907.2012.732163.
69. Bendell J.C., Lenz H.J., Ryan T. et al. Phase 1/2 study of KRN330, a fully hu-man anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs 2014;32(4):682-90. PMID: 24691674. DOI: 10.1007/s10637-014-0088-3.
70. Infante J.R., Bendell J.C., Goff L.W. et al. Safety, pharmacokinetics and pharmaco-dynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. Eur J Cancer 2013;49(6):1169—75. PMID: 23294608. DOI: 10.1016/j.ejca.2012.11.033.
71. Deming D.A., Cavalcante L.L., Lubner S.J. et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs 2016;34(2):168-75. PMID: 26666244. DOI: 10.1007/s10637-015-0314-7.
72. Sobrero A.F., Bordonaro R., Bencardino K. et al. Zivaflibercept (Z) in combi-nation with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program in pts pretreated with bevacizumab (B). J Clin Oncol 2015;3:528. DOI: 10.1200/jco.2015.33.3_suppl.528.
Review
Views:
3052
Email this article 